每周一次司美格鲁肽对比每日一次甘精胰岛素作为二甲双胍(联用或不联用磺脲类)附加治疗在未使用胰岛素的2型糖尿病患者中的疗效与安全性(SUSTAIN 4):一项随机、开放标签、平行组、多中心、多国、3a期试验
SUSTAIN 4研究在14国196个中心纳入1089例二甲双胍(联用或不联用磺脲类)控制不佳的未使用胰岛素2型糖尿病患者,随机接受每周一次0.5mg或1.0mg司美格鲁肽或每日一次甘精胰岛素治疗30周。与甘精胰岛素相比,司美格鲁肽显著降低HbA1c和体重,低血糖事件更少,安全性与其它GLP-1受体激动剂相似。
要点
- 司美格鲁肽0.5mg和1.0mg较甘精胰岛素显著降低HbA1c,估计治疗差异分别为-0.38%和-0.81%。
- 司美格鲁肽0.5mg和1.0mg较甘精胰岛素显著降低体重,估计治疗差异分别为-4.62kg和-6.33kg。
- 司美格鲁肽严重或血糖确证低血糖发生率低于甘精胰岛素,安全性与其它GLP-1受体激动剂相似。
核心结论
- 与甘精胰岛素相比,司美格鲁肽使HbA1c和体重降低更多,低血糖事件更少,耐受性良好,安全性与其它GLP-1受体激动剂相似。
研究设计与样本
- 随机、开放标签、非劣效性、平行组、多中心、多国3a期试验(SUSTAIN 4),在14个国家196个中心进行。
- 纳入年龄18岁及以上、二甲双胍单用或联用磺脲类血糖控制不佳的未使用胰岛素2型糖尿病患者1089例,按1:1:1随机分配。
- 干预为皮下每周一次司美格鲁肽0.5mg或1.0mg(固定剂量递增方案达到剂量)或每日一次甘精胰岛素(起始剂量每日10IU,每周滴定至早餐前自测血糖目标4.0-5.5mmol/L[72-99mg/dL]),治疗30周。
- 所有治疗组试验期间继续原有二甲双胍和磺脲类背景治疗;主要终点为基线至第30周平均HbA1c变化,确证性次要终点为基线至第30周平均体重变化;非劣效界值为HbA1c降低0.3%。
- 疗效和安全性在改良意向治疗人群(mITT;所有随机分配且至少接受一剂研究药物的参与者)中评估。
主要发现
- mITT人群包括司美格鲁肽0.5mg组362例、1.0mg组360例、甘精胰岛素组360例;提前终止治疗者分别为49例(14%)、55例(15%)和26例(7%)。
- 从平均基线HbA1c 8.17%(SD 0.89)起,第30周司美格鲁肽0.5mg和1.0mg分别降低1.21%(95%CI 1.10-1.31)和1.64%(1.54-1.74),甘精胰岛素降低0.83%(0.73-0.93);对比甘精胰岛素的估计治疗差异分别为-0.38%(95%CI -0.52至-0.24)和-0.81%(-0.96至-0.67),均p<0.0001。
- 平均基线体重93.45kg(SD 21.79);第30周司美格鲁肽0.5mg和1.0mg分别减重3.47kg(95%CI 3.00-3.93)和5.17kg(4.71-5.66),甘精胰岛素增重1.15kg(0.70-1.61);对比甘精胰岛素的估计治疗差异分别为-4.62kg(95%CI -5.27至-3.96)和-6.33kg(-6.99至-5.67),均p<0.0001。
- 严重或血糖确证低血糖报告例数:司美格鲁肽0.5mg组16例(4%)、1.0mg组20例(6%)、甘精胰岛素组38例(11%);0.5mg和1.0mg司美格鲁肽对比甘精胰岛素分别p=0.0021和p=0.0202;严重低血糖报告例数分别为2例(<1%)、5例(1%)和5例(1%)。
- 报告6例死亡:司美格鲁肽0.5mg组4例(1%)(3例心血管死亡,1例胰腺癌 assessed as possibly related to study medication),甘精胰岛素组2例(<1%)(均为心血管死亡);最常见不良事件为司美格鲁肽组恶心(0.5mg组77例[21%],1.0mg组80例[22%])和甘精胰岛素组鼻咽炎(44例[12%])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several pharmacological treatment options are available for type 2 diabetes; however, many patients do not achieve optimum glycaemic control and therefore new therapies are necessary. We assessed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical development, compared with insulin glargine in patients with type 2 diabetes who were inadequately controlled with metformin (with or without sulfonylureas). METHODS: We did a randomised, open-label, non-inferiority, parallel-group, multicentre, multinational, phase 3a trial (SUSTAIN 4) at 196 sites in 14 countries. Eligible participants were insulin-naive patients with type 2 diabetes, aged 18 years and older, who had insufficient glycaemic control with metformin either alone or in combination with a sulfonylurea. We randomly assigned participants (1:1:1) to either subcutaneous once-weekly 0·5 mg or 1·0 mg semaglutide (doses reached after following a fixed dose-escalation regimen) or once-daily insulin glargine (starting dose 10 IU per day, then titrated weekly to a pre-breakfast self-measured plasma glucose target of 4·0-5·5 mmol/L [72-99 mg/dL]) for 30 weeks. In all treatment groups, previous background metformin and sulfonylurea treatment was continued throughout the trial. We did the randomisation using an interactive voice or web response system. The primary endpoint was change in mean HbA1c from baseline to week 30 and the confirmatory secondary endpoint was the change in mean bodyweight from baseline to week 30. We assessed efficacy and safety in the modified intention-to-treat population (mITT; all randomly assigned participants who were exposed to at least one dose of study drug) and used a margin of 0·3% to establish non-inferiority in HbA1c reduction. This trial is registered with ClinicalTrials.gov, number NCT02128932. FINDINGS: Between Aug 4, 2014, and Sept 3, 2015, we randomly assigned 1089 participants to treatment; the mITT population consisted of 362 participants assigned to 0·5 mg semaglutide, 360 to 1·0 mg semaglutide, and 360 to insulin glargine. 49 (14%) participants assigned to 0·5 mg semaglutide discontinued treatment prematurely, compared with 55 (15%) assigned to 1·0 mg semaglutide, and 26 (7%) assigned to insulin glargine. Most discontinuations were due to adverse events-mostly gastrointestinal with semaglutide, and others such as skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine. From a mean baseline HbA1c of 8·17% (SD 0·89), at week 30, 0·5 and 1·0 mg semaglutide achieved reductions of 1·21% (95% CI 1·10-1·31) and 1·64% (1·54-1·74), respectively, versus 0·83% (0·73-0·93) with insulin glargine; estimated treatment difference versus insulin glargine -0·38% (95% CI -0·52 to -0·24) with 0·5 mg semaglutide and -0·81% (-0·96 to -0·67) with 1·0 mg semaglutide (both p<0·0001). Mean bodyweight at baseline was 93·45 kg (SD 21·79); at week 30, 0·5 and 1·0 mg semaglutide achieved weight losses of 3·47 kg (95% CI 3·00-3·93) and 5·17 kg (4·71-5·66), respectively, versus a weight gain of 1·15 kg (0·70-1·61) with insulin glargine; estimated treatment difference versus insulin glargine -4·62 kg (95% CI -5·27 to -3·96) with 0·5 mg semaglutide and -6·33 kg (-6·99 to -5·67) with 1·0 mg semaglutide (both p<0·0001). Severe or blood glucose-confirmed hypoglycaemia was reported by 16 (4%) participants with 0·5 mg semaglutide and 20 (6%) with 1·0 mg semaglutide versus 38 (11%) with insulin glargine (p=0·0021 and p=0·0202 for 0·5 mg and 1·0 mg semaglutide vs insulin glargine, respectively). Severe hypoglycaemia was reported by two (<1%) participants with 0·5 mg semaglutide, five (1%) with 1·0 mg semaglutide, and five (1%) with insulin glargine. Six deaths were reported: four (1%) in the 0·5 mg semaglutide group (three cardiovascular deaths, one pancreatic carcinoma, which was assessed as being possibly related to study medication) and two (<1%) in the insulin glargine group (both cardiovascular death). The most frequently reported adverse events were nausea with semaglutide, reported in 77 (21%) patients with 0·5 mg and in 80 (22%) with 1·0 mg, and nasopharyngitis reported in 44 (12%) patients with insulin glargine. INTERPRETATION: Compared with insulin glargine, semaglutide resulted in greater reductions in HbA1c and weight, with fewer hypoglycaemic episodes, and was well tolerated, with a safety profile similar to that of other GLP-1 receptor agonists. FUNDING: Novo Nordisk A/S.
引用
- Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017. PMID: 28344112. doi:10.1016/S2213-8587(17)30085-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。